Compile Data Set for Download or QSAR
Report error Found 1864 with Last Name = 'mönning' and Initial = 'u'
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555115(US11339157, Example 9 | 3-[(3,5-difluorophenyl)ami...)
Affinity DataIC50: 0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555116(US11339157, Example 10 | 3-[(3,5-difluorophenyl)am...)
Affinity DataIC50: 0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555110(US11339157, Example 4 | 3-[(3-fluorophenyl)amino]-...)
Affinity DataIC50: 0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555112(US11339157, Example 6 | 3-[(3-fluorophenyl)amino]-...)
Affinity DataIC50: 0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555118(US11339157, Example 12 | 3-[(2-bromo-3-fluoropheny...)
Affinity DataIC50: 0.0860nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555136(US11339157, Example 30 | 3-[(3,5-difluoro-2-methox...)
Affinity DataIC50: 0.0970nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555137(US11339157, Example 31 | 3-[(3,5-difluoro-2-methox...)
Affinity DataIC50: 0.0990nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555123(US11339157, Example 17 | 3-[(3-fluoro-2-methoxyphe...)
Affinity DataIC50: 0.113nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555124(US11339157, Example 18 | 3-{[2-(difluoromethoxy)-3...)
Affinity DataIC50: 0.120nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555110(US11339157, Example 4 | 3-[(3-fluorophenyl)amino]-...)
Affinity DataIC50: 0.131nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555127(US11339157, Example 21 | 3-[(3-fluoro-2-methylphen...)
Affinity DataIC50: 0.138nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555122(US11339157, Example 16 | 3-[(3-fluoro-2-methoxyphe...)
Affinity DataIC50: 0.138nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555126(US11339157, Example 20 | 3-[(3-fluoro-2-methylphen...)
Affinity DataIC50: 0.149nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555125(US11339157, Example 19 | 3-{[2-(difluoromethoxy)-3...)
Affinity DataIC50: 0.155nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555137(US11339157, Example 31 | 3-[(3,5-difluoro-2-methox...)
Affinity DataIC50: 0.161nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555128(US11339157, Example 22 | 3-{[2-(2,2-difluoroethyl)...)
Affinity DataIC50: 0.176nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555123(US11339157, Example 17 | 3-[(3-fluoro-2-methoxyphe...)
Affinity DataIC50: 0.177nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555136(US11339157, Example 30 | 3-[(3,5-difluoro-2-methox...)
Affinity DataIC50: 0.209nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555122(US11339157, Example 16 | 3-[(3-fluoro-2-methoxyphe...)
Affinity DataIC50: 0.212nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555112(US11339157, Example 6 | 3-[(3-fluorophenyl)amino]-...)
Affinity DataIC50: 0.212nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555127(US11339157, Example 21 | 3-[(3-fluoro-2-methylphen...)
Affinity DataIC50: 0.213nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555118(US11339157, Example 12 | 3-[(2-bromo-3-fluoropheny...)
Affinity DataIC50: 0.218nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555117(US11339157, Example 11 | 3-{[2-(difluoromethoxy)ph...)
Affinity DataIC50: 0.220nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555125(US11339157, Example 19 | 3-{[2-(difluoromethoxy)-3...)
Affinity DataIC50: 0.239nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555135(US11339157, Example 29 | 3-[(3,4-difluoro-2-methox...)
Affinity DataIC50: 0.246nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555129(US11339157, Example 23 | 3-{[2-(2,2-difluoroethyl)...)
Affinity DataIC50: 0.259nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

LigandPNGBDBM571467((+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3...)
Affinity DataIC50: 0.260nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555132(US11339157, Example 26 | 3-[(2-ethoxy-3-fluorophen...)
Affinity DataIC50: 0.268nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555103(US11339157, Example 3 | 2-[3-(benzyloxy)pyridin-4-...)
Affinity DataIC50: 0.280nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555124(US11339157, Example 18 | 3-{[2-(difluoromethoxy)-3...)
Affinity DataIC50: 0.300nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555128(US11339157, Example 22 | 3-{[2-(2,2-difluoroethyl)...)
Affinity DataIC50: 0.309nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555114(US11339157, Example 8 | 3-[(3-fluorophenyl)amino]-...)
Affinity DataIC50: 0.310nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

LigandPNGBDBM562371(US11401278, Example 44 | US11401278, Example 46 | ...)
Affinity DataIC50: 0.310nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555126(US11339157, Example 20 | 3-[(3-fluoro-2-methylphen...)
Affinity DataIC50: 0.322nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

LigandPNGBDBM571478((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.330nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM562401(US11401278, Example 72 | 4-chloro-3-ethyl-7-{3-[(6...)
Affinity DataIC50: 0.340nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562369(US11401278, Example 42 | (−)-4-chloro-14-cyc...)
Affinity DataIC50: 0.340nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM555129(US11339157, Example 23 | 3-{[2-(2,2-difluoroethyl)...)
Affinity DataIC50: 0.342nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
US Patent

LigandPNGBDBM571511((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM571483((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM571480((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 0.390nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM562377(US11401278, Example 48 | US11401278, Example 65 | ...)
Affinity DataIC50: 0.400nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM571489((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.410nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM571514((+)-4-chloro-15-[2-(3,3-difluoroazetidin-1-yl)ethy...)
Affinity DataIC50: 0.420nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Human)
The Broad Institute

US Patent
LigandPNGBDBM544485((rac)-12-ethyl-13-fluoro-1-(3-((6-fluoronaphthalen...)
Affinity DataIC50: 0.450nMAssay Description:MCL-1 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
US Patent

LigandPNGBDBM571525((+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluor...)
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM571497(4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox...)
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM571486((+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

LigandPNGBDBM562386(US11401278, Example 57 | (+)-4-chloro-3,14-diethyl...)
Affinity DataIC50: 0.480nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM571473((rac)-4-chloro-(15-rac)-(2-methoxyethyl)-2,3-dimet...)
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

Displayed 1 to 50 (of 1864 total ) | Next | Last >>
Jump to: